Secondary prevention trials in Alzheimer disease: the challenge of identifying a meaningful end point.
作者信息
Kryscio Richard J
机构信息
Departments of Statistics and Biostatistics and the Sanders-Brown Center on Aging, University of Kentucky, Lexington.
出版信息
JAMA Neurol. 2014 Aug;71(8):947-9. doi: 10.1001/jamaneurol.2014.1120.
Abstract
摘要
相似文献
1
Secondary prevention trials in Alzheimer disease: the challenge of identifying a meaningful end point.
JAMA Neurol. 2014 Aug;71(8):947-9. doi: 10.1001/jamaneurol.2014.1120.
2
The preclinical Alzheimer cognitive composite: measuring amyloid-related decline.
JAMA Neurol. 2014 Aug;71(8):961-70. doi: 10.1001/jamaneurol.2014.803.
3
Disease staging and milestones.
Can J Neurol Sci. 2007 Mar;34 Suppl 1:S62-6. doi: 10.1017/s031716710000559x.
4
The amyloid hypothesis for Alzheimer's disease: a critical reappraisal.
J Neurochem. 2009 Aug;110(4):1129-34. doi: 10.1111/j.1471-4159.2009.06181.x. Epub 2009 May 18.
5
Mild cognitive impairment (MCI) represents early-stage Alzheimer's disease.
J Alzheimers Dis. 2005 Jun;7(3):235-9; discussion 255-62. doi: 10.3233/jad-2005-7306.
6
Use of High-Frequency In-Home Monitoring Data May Reduce Sample Sizes Needed in Clinical Trials.
PLoS One. 2015 Sep 17;10(9):e0138095. doi: 10.1371/journal.pone.0138095. eCollection 2015.
7
Alzheimer disease: before the diagnosis.
Neurology. 2013 Mar 26;80(13):e148-9. doi: 10.1212/WNL.0b013e31828cade3.
8
Identifying cost-effective predictive rules of amyloid-β level by integrating neuropsychological tests and plasma-based markers.
J Alzheimers Dis. 2015;43(4):1261-70. doi: 10.3233/JAD-140705.
9
Amyloid-dependent and amyloid-independent stages of Alzheimer disease.
Arch Neurol. 2011 Aug;68(8):1062-4. doi: 10.1001/archneurol.2011.70. Epub 2011 Apr 11.
10
Benefits of cognitive-motor intervention in MCI and mild to moderate Alzheimer disease.
Neurology. 2005 Jul 26;65(2):338-9; author reply 338-9. doi: 10.1212/wnl.65.2.338.
引用本文的文献
1
Association of Stages of Objective Memory Impairment With Incident Symptomatic Cognitive Impairment in Cognitively Normal Individuals.
Neurology. 2023 May 30;100(22):e2279-e2289. doi: 10.1212/WNL.0000000000207276. Epub 2023 Apr 19.
2
Plasma amyloid-β42/40 and apolipoprotein E for amyloid PET pre-screening in secondary prevention trials of Alzheimer's disease.
Brain Commun. 2023 Jan 24;5(2):fcad015. doi: 10.1093/braincomms/fcad015. eCollection 2023.
3
Evidence-based prevention of Alzheimer's disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials.
J Neurol Neurosurg Psychiatry. 2020 Nov;91(11):1201-1209. doi: 10.1136/jnnp-2019-321913. Epub 2020 Jul 20.
4
Composite cognitive and functional measures for early stage Alzheimer's disease trials.
Alzheimers Dement (Amst). 2020 May 15;12(1):e12017. doi: 10.1002/dad2.12017. eCollection 2020.
5
Cognitive composite score association with Alzheimer's disease plaque and tangle pathology.
Alzheimers Res Ther. 2018 Sep 11;10(1):90. doi: 10.1186/s13195-018-0401-z.
6
Association of Antioxidant Supplement Use and Dementia in the Prevention of Alzheimer's Disease by Vitamin E and Selenium Trial (PREADViSE).
JAMA Neurol. 2017 May 1;74(5):567-573. doi: 10.1001/jamaneurol.2016.5778.
7
Aerobic exercise for Alzheimer's disease: A randomized controlled pilot trial.
PLoS One. 2017 Feb 10;12(2):e0170547. doi: 10.1371/journal.pone.0170547. eCollection 2017.
8
Sensitivity of composite scores to amyloid burden in preclinical Alzheimer's disease: Introducing the Z-scores of Attention, Verbal fluency, and Episodic memory for Nondemented older adults composite score.
Alzheimers Dement (Amst). 2015 Dec 12;2:19-26. doi: 10.1016/j.dadm.2015.11.003. eCollection 2016.
9
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria.
Alzheimers Dement. 2016 Mar;12(3):292-323. doi: 10.1016/j.jalz.2016.02.002.
10
Risk of dementia and death in the long-term follow-up of the Pittsburgh Cardiovascular Health Study-Cognition Study.
Alzheimers Dement. 2016 Feb;12(2):170-183. doi: 10.1016/j.jalz.2015.08.165. Epub 2015 Oct 28.
本文引用的文献
1
The preclinical Alzheimer cognitive composite: measuring amyloid-related decline.
JAMA Neurol. 2014 Aug;71(8):961-70. doi: 10.1001/jamaneurol.2014.803.
2
Combining Multiple Markers to Improve the Longitudinal Rate of Progression-Application to Clinical Trials on the Early Stage of Alzheimer's Disease.
Stat Biopharm Res. 2013 Jan 1;5(1). doi: 10.1080/19466315.2012.756662.
3
Clinical trials in predementia stages of Alzheimer disease.
Med Clin North Am. 2013 May;97(3):439-57. doi: 10.1016/j.mcna.2013.01.002. Epub 2013 Feb 22.
4
Can we prevent Alzheimer's disease? Secondary "prevention" trials in Alzheimer's disease.
Alzheimers Dement. 2013 Mar;9(2):123-131.e1. doi: 10.1016/j.jalz.2012.12.004. Epub 2013 Feb 12.
5
Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI).
Brain Imaging Behav. 2012 Dec;6(4):502-16. doi: 10.1007/s11682-012-9186-z.
6
Power calculations for clinical trials in Alzheimer's disease.
J Alzheimers Dis. 2011;26 Suppl 3(Suppl 3):369-77. doi: 10.3233/JAD-2011-0062.
7
Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials.
Alzheimers Dement. 2010 Sep;6(5):367-77. doi: 10.1016/j.jalz.2010.07.004.
8
The Alzheimer's Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomes.
Alzheimers Dement. 2010 May;6(3):257-64. doi: 10.1016/j.jalz.2010.03.002.
9
Memory impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer's disease.
J Int Neuropsychol Soc. 2008 Mar;14(2):266-78. doi: 10.1017/S1355617708080302.
10
Designing a large prevention trial: statistical issues.
Stat Med. 2004 Jan 30;23(2):285-96. doi: 10.1002/sim.1716.
Zotero 插件